Journal article : Review

The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy

Abstract:: This review discusses the role of chronic human cytomegalovirus (HCMV) infection in patients receiving immune checkpoint blockade (ICB) treatment against different malignancies, with an especial focus on malignant melanoma. We briefly outline the impact of HCMV infection on the immune system as an entity before exploring its role in the context of cancer. We then address the potential impact on the efficacy of immunotherapeutic agents, particularly ICB, before looking at development of ICB-related autoimmune toxicity. Finally, we discuss potential avenues for future research. This article is part of the discussion meeting issue ‘The indirect effects of cytomegalovirus infection: mechanisms and consequences’.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Bremke, J., Jay, C., Little, M., & Fairfax, B. P. (2025). The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy. Philosophical Transactions of the Royal Society B: Biological Sciences, 380(1938).

MLA Style

Bremke, J, et al. “The Immunomodulatory Role of Human Cytomegalovirus in Cancer in the Era of Checkpoint Immunotherapy.” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 380, no. 1938, 2025.

Chicago Style

Bremke, J, C Jay, M Little, and BP Fairfax. 2025. “The Immunomodulatory Role of Human Cytomegalovirus in Cancer in the Era of Checkpoint Immunotherapy.” Philosophical Transactions of the Royal Society B: Biological Sciences 380 (1938).
Print

Access Document

Files:: Bremke_et_al_2025_The_immunomodulatory_role.pdf

(Preview, Version of record, pdf, 2.0MB, Terms of use)

Publisher copy:: 10.1098/rstb.2024.0413

Authors

+ Bremke, J More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Oncology
Sub department:: Oncology
Role:: Author
ORCID:: 0009-0002-2772-7675

+ Jay, C More by this author

Institution:: University of Oxford
Oxford college:: Somerville College
Role:: Author

+ Little, M More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Oncology
Sub department:: Oncology
Role:: Author
ORCID:: 0000-0003-2592-1570

+ Fairfax, BP More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Oncology
Sub department:: Oncology
Role:: Author
ORCID:: 0000-0001-7413-5002

+ Cancer Research UK More from this funder

Funder identifier:: https://ror.org/054225q67

+ Wellcome Trust More from this funder

Funder identifier:: https://ror.org/029chgv08

Publisher:: The Royal Society
Journal:: Philosophical Transactions of the Royal Society B: Biological Sciences More from this journal
Volume:: 380
Issue:: 1938
Article number:: 20240413
Publication date:: 2025-11-06
Acceptance date:: 2025-07-29
DOI:: 10.1098/rstb.2024.0413
EISSN:: 1471-2970
ISSN:: 0962-8436

Language:: English
Keywords:: cancer

immunotherapy

infection
Subtype:: Review
Pubs id:: 2320562
UUID:: uuid_2a66917a-bbe7-4735-81c7-89702e82d734
Local pid:: pubs:2320562
Source identifiers:: 3445941
Deposit date:: 2025-11-06
ARK identifier:: ark:/29072/ora_2a66917abbe7473581c789702e82d734

Terms of use

Copyright date:: 2025

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP